BioNotebook: Allergan's first Restasis challenge, Exelixis offering, Celladon IPO, EnVivo Phase III
This article was originally published in Scrip
Executive Summary
The much-anticipated battle to bring generic Restasis (cyclosporine) to market has begun: Actavis subsidiary Watson Laboratories filed an abbreviated new drug application (ANDA) challenging Allergan's recently issued formulation patent for the top-selling dry eye drug.